Catalyst Wire Dossier Catalyst Wire Dossier

Parvovirus H-1 (ParvOryx)

Parvovirus H-1 · Oryx GmbH & Co. KG
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Parvovirus H-1 (ParvOryx), covering 2022-11-21 to 2022-11-21. Get the full timeline:

Most recent: Clinical Trial Update: Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. [Phase 1, Phase 2]

See pricing